ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.425,31
-1,20%
S&P 500
5.354,14
0,02%
US Dollar vs BRL
5,2921
0,64%
Bitcoin
68.796,00
-2,79%
Brent Oil
79,515
-0,46%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Pear Therapeutics Inc (PEAR)

  7. Pear Therapeutics Inc (PEAR) Notícias

PEAR

Pear Therapeutics (PEAR)

Pear Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PEAR
DataHoraFonteTítuloCódigoCompanhia
02/05/202314:37Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:PEARPear Therapeutics Inc
12/04/202317:34Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:PEARPear Therapeutics Inc
10/04/202317:37Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PEARPear Therapeutics Inc
07/04/202312:30Business WirePear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales ProcessNASDAQ:PEARPear Therapeutics Inc
03/04/202317:05GlobeNewswire Inc.Sight Sciences Appoints Ali Bauerlein as Chief Financial OfficerNASDAQ:PEARPear Therapeutics Inc
31/03/202317:04Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PEARPear Therapeutics Inc
17/03/202310:15Business WirePear Therapeutics Announces Process Exploring Strategic AlternativesNASDAQ:PEARPear Therapeutics Inc
27/02/202310:00Business WirePear Therapeutics to Participate in 43rd Annual Cowen Healthcare ConferenceNASDAQ:PEARPear Therapeutics Inc
09/02/202318:43Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PEARPear Therapeutics Inc
02/02/202310:00Business WirePear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceNASDAQ:PEARPear Therapeutics Inc
26/01/202310:00Business WirePear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use DisordersNASDAQ:PEARPear Therapeutics Inc
24/01/202318:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PEARPear Therapeutics Inc
18/01/202310:00Business WirePear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug ListNASDAQ:PEARPear Therapeutics Inc
17/01/202310:00Business WirePear Therapeutics to Participate in Citi’s BioTech C-Suite Virtual Fireside Chat SeriesNASDAQ:PEARPear Therapeutics Inc
12/01/202310:00Business WireCalifornia Department of Health Care Services Awards Contract to Pear Therapeutics to Support the Recovery Incentives ProgramNASDAQ:PEARPear Therapeutics Inc
10/01/202318:21Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PEARPear Therapeutics Inc
10/01/202310:00Business WirePear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital TherapeuticsNASDAQ:PEARPear Therapeutics Inc
04/01/202318:21Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:PEARPear Therapeutics Inc
04/01/202310:00Business WirePear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery Across Multiple Locations and StatesNASDAQ:PEARPear Therapeutics Inc
04/01/202308:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PEARPear Therapeutics Inc
03/01/202309:38Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:PEARPear Therapeutics Inc
15/12/202210:00Business WirePear Therapeutics Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using reSET® at AAAPNASDAQ:PEARPear Therapeutics Inc
21/11/202210:00Business WirePear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx ConferenceNASDAQ:PEARPear Therapeutics Inc
14/11/202221:45TipRanksPear Therapeutics (PEAR) Receives a Buy from BTIGNASDAQ:PEARPear Therapeutics Inc
14/11/202219:53Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PEARPear Therapeutics Inc
14/11/202218:02Business WirePear Therapeutics Reports Third Quarter 2022 ResultsNASDAQ:PEARPear Therapeutics Inc
10/11/202210:00Business WirePear Therapeutics to Participate in the BTIG Digital Health ForumNASDAQ:PEARPear Therapeutics Inc
07/11/202210:00Business WirePear Therapeutics Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR EuropeNASDAQ:PEARPear Therapeutics Inc
03/11/202209:00Business WireState of Wisconsin to Provide Access to Prescription Digital Therapeutics to Help Local Communities Fight Against Addiction CrisisNASDAQ:PEARPear Therapeutics Inc
01/11/202217:02Business WirePear Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare ConferenceNASDAQ:PEARPear Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PEAR

Seu Histórico Recente

UNSW3
REIETH
Zerogoki Token
NYSE
UHS
Universal Health Services
BIT
F17837
Vontobel Financial Produ...
USOTC
FBASF
Deutsche Bank Mexico SA ... (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados